期刊
FUTURE ONCOLOGY
卷 9, 期 12, 页码 1819-1827出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.13.220
关键词
cutaneous; depsipeptide; histone deacetylase inhibitor; lymphoma; romidepsin
类别
资金
- Celgene Corporation
Cutaneous T-cell lymphomas are relatively rare lymphomas and the most common form is mycosis fungoides. Its rare leukemic variant is Sezary syndrome. Advanced-stage disease is typically treated with bexarotene (a retinoid), IFN-alpha or conventional chemotherapeutic agents, but relapses are inevitable. Histone deacetylase inhibitors that modify the epigenome are an attractive addition to the armamentarium. Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据